share_log

B of A Securities Downgrades Beam Therapeutics to Neutral, Announces $35 Price Target

Benzinga ·  Dec 15, 2023 21:37

B of A Securities analyst Greg Harrison downgrades Beam Therapeutics (NASDAQ:BEAM) from Buy to Neutral and announces $35 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment